Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly (NYSE: LLY) has announced plans to build four new pharmaceutical manufacturing sites in the United States, bringing its total U.S. capital expansion commitments to over $50 billion since 2020. Three sites will focus on active pharmaceutical ingredients (API) manufacturing and chemical synthesis, while the fourth will expand injectable therapy production.

The expansion will create 3,000 high-skilled jobs including engineers, scientists, and technicians, plus approximately 10,000 construction jobs. The new facilities will manufacture medicines across therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience.

This investment builds upon Lilly's previous domestic expansion commitments of $23 billion from 2020-2024, which included facilities in North Carolina, Indiana, and Wisconsin. The company is currently negotiating with several states and welcomes additional interest by March 12, 2025. Production at the new facilities is expected to begin within five years.

Eli Lilly and Company (NYSE: LLY) has announced the launch of new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials for $499 per month through the new Zepbound Self Pay Journey Program. The company has also reduced prices of existing 2.5 mg vials to $349 and 5 mg vials to $499 per month.

These offerings are available exclusively through LillyDirect Self Pay Pharmacy Solutions, which provides transparent pricing by eliminating third-party supply chain entities and allowing patients to access savings directly outside of insurance.

The Zepbound Self Pay Journey Program reduces the regular prices of 7.5 mg ($599) and 10 mg ($699) doses to $499 per month at first fill and refills occurring within 45 days of prior delivery.

Zepbound is also available in various dosages in single-dose pen autoinjectors, with recommended maintenance dosages of 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.

Eli Lilly (NYSE: LLY) has announced its participation in TD Cowen's 45th Annual Health Care Conference scheduled for March 4, 2025. Jake Van Naarden, executive vice president and president of Lilly Oncology, will participate in a fireside chat at 1:50 p.m. Eastern time.

The event will be accessible through a live audio webcast on Lilly's investor website under the 'Webcasts & Presentations' section. Investors and interested parties can access the replay of the presentation on the same platform for approximately 90 days following the event.

Eli Lilly (NYSE: LLY) announced positive two-year results from the VIVID-2 study for Omvoh® (mirikizumab-mrkz) in treating Crohn's disease. The study showed remarkable sustained efficacy, with 92.9% of patients maintaining clinical remission and 87.6% maintaining endoscopic response after two years of continuous treatment.

Among patients not in remission at year one, 60.8% achieved clinical remission and 35.4% gained endoscopic remission during the second year. The safety profile remained consistent, with only 6.8% reporting serious adverse events and 0.8% discontinuing treatment due to adverse events.

Omvoh, which targets IL-23p19 protein to reduce gastrointestinal inflammation, received FDA approval for Crohn's disease in January 2025 and is already approved in 44 countries for ulcerative colitis treatment. It's the first IL-23p19 antagonist demonstrating long-term efficacy for both conditions.

Eli Lilly (LLY) reported strong Q4 2024 financial results with revenue increasing 45% to $13.53 billion, primarily driven by Mounjaro and Zepbound sales. Q4 EPS grew 102% to $4.88 on a reported basis and 114% to $5.32 on a non-GAAP basis.

The company received FDA approval for Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity and Omvoh for Crohn's disease. Notable developments include a pending acquisition of Scorpion Therapeutics' PI3Kα inhibitor program and a $15 billion share repurchase program.

For 2025, Lilly provided guidance with revenue expected between $58.0-61.0 billion, representing approximately 32% growth compared to 2024. EPS guidance for 2025 is set at $22.05-23.55 on a reported basis and $22.50-24.00 on a non-GAAP basis.

Eli Lilly (NYSE: LLY) has scheduled the announcement of its fourth-quarter 2024 financial results and 2025 financial guidance for February 6, 2025. The company will host a conference call at 10 a.m. Eastern time on the same day to discuss the results with investors, media, and the general public.

A live webcast of the conference call will be accessible through Lilly's investor relations website, with a replay available afterward for those unable to attend the live event.

Eli Lilly (NYSE: LLY) has received FDA approval for Omvoh® (mirikizumab-mrkz) to treat moderately to severely active Crohn's disease in adults. This approval follows its October 2023 authorization for ulcerative colitis treatment. The drug targets interleukin-23p19 protein to reduce gastrointestinal inflammation.

In the Phase 3 VIVID-1 trial, 53% of Omvoh-treated patients achieved clinical remission at one year versus 36% on placebo, and 46% showed intestinal lining healing compared to 23% on placebo. Among patients achieving clinical remission and endoscopic response at one year, nearly 90% maintained clinical remission after two years of continuous treatment.

The drug's safety profile aligns with its known characteristics in ulcerative colitis patients. Common side effects include upper respiratory tract infections, injection site reactions, headache, arthralgia, and elevated liver tests.

Eli Lilly (LLY) has updated its revenue guidance for 2024 and announced expectations for 2025. The company projects 2024 full-year revenue of approximately $45.0 billion, representing 32% growth from the previous year, though Q4 2024 revenue is expected to be $13.5 billion, about $400 million below recent guidance.

For 2025, Lilly anticipates revenue between $58.0-61.0 billion, a 32% growth at midpoint compared to 2024. Q4 2024 performance includes approximately $3.5 billion from Mounjaro® and $1.9 billion from Zepbound®, with non-incretin revenue growing 20% compared to Q4 2023.

The company attributes the Q4 2024 guidance miss to slower-than-expected incretin market growth and lower channel inventory. Lilly expects continued momentum in 2025, planning to increase incretin production by at least 60% in the first half of 2025 compared to the same period in 2024.

Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire Scorpion Therapeutics' PI3Kα inhibitor program STX-478, a precision oncology treatment currently in Phase 1/2 clinical trials. The deal, valued at up to $2.5 billion, includes upfront payment and milestone-based subsequent payments.

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor being evaluated for breast cancer and other advanced solid tumors. The treatment could potentially benefit 30-40% of people with hormone-positive breast cancer by selectively targeting cancerous cells while sparing healthy ones, potentially offering better disease control and improved tolerability compared to current treatments.

As part of the transaction, Scorpion will spin out a new independent entity to retain its employees and non-PI3Kα pipeline assets, with Lilly maintaining a minority equity stake. The new company will be led by Dr. Friedman and the current Scorpion management team.